No Data
Rundu Co., Ltd.: 2024 performance forecast
Zhuhai Rundu Pharmaceutical (002923.SZ): Net income for the year 2024 is expected to decline by 40.21% to 58.15%.
On January 22, Gelonghui reported that Zhuhai Rundu Pharmaceutical (002923.SZ) announced its earnings forecast for 2024, estimating Net income attributable to shareholders of the listed company to be 28 million to 40 million yuan, a decrease of 40.21% to 58.15% compared to the same period last year; Net income after deducting non-recurring gains and losses is expected to be 18 million to 25 million yuan, a decrease of 42.16% to 58.35% compared to the same period last year; Basic EPS is projected to be 0.08 to 0.12 yuan per share. Affected by industry policies and market fluctuations, especially the impact of the national centralized procurement policy, mainly in formulations.
Here's Why Zhuhai Rundu Pharmaceutical (SZSE:002923) Has A Meaningful Debt Burden
Zhuhai Rundu Pharmaceutical (002923.SZ): The subsidiary Zhuhai Rundu Pharmaceutical (Jingmen) Co., Ltd. produces nicotine, which includes synthetic nicotine and extracted nicotine.
On December 18, Glonghui reported that Zhuhai Rundu Pharmaceutical (002923.SZ) stated on the investor interaction platform that its subsidiary, Rundu Pharmaceutical (Jingmen) Co., Ltd., produces nicotine both from synthetic sources and extraction.
Rundu Pharmaceutical Gets Regulatory Nod to Add Specification for Irbesartan Tablets
Zhuhai Rundu Pharmaceutical's (SZSE:002923) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Zhuhai Rundu Pharmaceutical Co., Ltd.'s (SZSE:002923) 25% Dip In Price Shows Sentiment Is Matching Earnings
